This video is normally available to paying customers.
You may unlock this video for FREE. Enter your email address for instant access AND to receive ongoing updates and special discounts related to this topic.
Childhood to Adulthood:
Peanut allergies are on the rise, affecting children and often persisting into adulthood. Severe cases can be life-threatening.
Exploring AR101:
A groundbreaking study is underway to assess the effectiveness of the AR101 drug in mitigating symptoms of severe peanut allergies.
How AR101 Works:
AR101, a peanut protein-based drug, gradually increases the dose to build tolerance. It doesn't cure peanut allergies but aims to reduce the risk of severe reactions upon peanut exposure.
Licensed Treatment:
AR101 has gained approval from the US Food and Drug Administration (FDA) for reducing allergic reaction incidence and severity in patients aged 4-17 with peanut allergies.
Extensive Trial:
The study involved 555 participants, including 499 children and 56 adults, across 10 countries in North America and Europe. AR101 was compared to a placebo, with both groups undergoing gradual increases over a year.
Safe Clinical Environment:
During the trial, all tolerance tests were conducted under medical supervision in research facilities, ensuring immediate medical attention for severe allergic reactions.
Reduced Severity and Improved Tolerance:
Results indicate that young individuals with peanut allergies experienced a decrease in symptom severity and an enhanced ability to tolerate small amounts of peanut protein with AR101 treatment compared to the placebo. However, the drug did not significantly impact adults, with the reason still under investigation.
Promising Future:
Ongoing studies are dedicated to finding solutions for serious peanut allergies, offering hope to affected individuals and their families. It's crucial to highlight that tolerance testing should never be attempted at home due to the life-threatening nature of allergic reactions.
